Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-head phase IIIb study of guselkumab versus risankizumab in moderately to severely active Crohn's disease
CTR20261048Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab, risankizumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
guselkumabrisankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20261048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261048.